Apel­lis coun­ters Alex­ion’s cri­tique, clears up FDA ques­tions as block­buster de­ci­sion looms

In Jan­u­ary, when Apel­lis re­vealed da­ta that showed their drug pegc­eta­coplan out­per­formed Alex­ion’s com­pa­ny-build­ing block­buster Soliris in treat­ing a rare blood dis­or­der called PNH …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER